Startup
Focused on revolutionising treatment of neurodegenerative diseases.
Melbourne, VIC
Every investor coverage indicates participated in a round Neurizon Therapeutics Limited raised.
Companies Neurizon Therapeutics Limited acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Chris Bremer | Chief Executive Officer | Biotech Dispatch (1 Oct 2026), Biotech Dispatch (7 Sep 2026) |
| Sergio Duchini | Interim Executive Chairman | Biotech Dispatch |
| Sergio Duchini | Chair | Biotech Dispatch (1 Oct 2026), Biotech Dispatch (7 Sep 2026) |
Stories naming Neurizon Therapeutics Limited. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Neurizon Therapeutics appoints Chris Bremer as CEO while interim executive chairman Sergio Duchini becomes non-executive chairman, with the company's ALS drug awaiting Phase 2/3 trial results in 2027.
America's NIH has agreed to fund a program giving up to 200 ALS patients access to Neurizon Therapeutics' drug NUZ-001, with Melbourne-based Neurizon as subawardee and a Boston ALS centre running it.
Neurizon Therapeutics, a Melbourne biotech developing an ALS treatment, has appointed industry veteran Dr Chris Bremer as CEO as its lead drug NUZ-001 heads toward Phase 2/3 trial results in 2027.
Health technology governance veteran Sergio Duchini joins ANDHealth's board, adding capital markets and R&D commercialisation expertise to the digital health accelerator.